From October 23 to 24, 2025, the 2025 Complex Cardiovascular Therapeutics (CCT 2025) was grandly held in Kobe, Japan. As one of the most influential academic conferences on cardiovascular interventional therapy in Asia, it shares the latest advancements in PCI therapy, structural heart disease, and surgical treatment through live surgical demonstrations, special seminars, and academic reports. The conference attracts cardiovascular experts from around the world and has become an internationally recognized high-level academic exchange platform.

As one of the few Chinese manufacturers exhibiting at CCT, Kossel made a focused appearance with a range of star products and localized solutions, showcasing the company’s latest technologies and achievements to medical professionals.

Kossel’s exhibition team received doctors and agents from Japan and other Asian countries during the conference, and conducted in-depth exchanges on concepts, strategies, new devices, and clinical research.

Focused on the pan-vascular intervention field, Kossel has been committed to bringing original Chinese medical technologies and achievements to more doctors and patients. In 2021, Kossel’s PTCA balloon obtained certification in Japan. In addition, Japan serves as one of the clinical centers for Kossel’s coronary product, the MiStent® coronary drug-eluting stent, which has gained partial market recognition and laid a foundation for product promotion. More localized products and solutions will be developed and launched in the future.

Going forward, Kossel will continue to deepen innovative R&D in the pan-vascular intervention field, advance the layout of the Asian market simultaneously, and focus closely on application needs in the pan-vascular intervention sector. It aims to provide more innovative and practical products and solutions for doctors and patients in Asia and beyond.